(Q46440869)

English

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

scientific article published on 7 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

0 references

Norma C. Gutiérrez

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

Lourdes Cordón

object named as

L Cordón

8

0 references

object named as

A Oriol

11

0 references

22

object named as

A Orfao

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

author name string

B Paiva

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

M-B Vídriales

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

L Rosiñol

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

J Martínez-López

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

M-V Mateos

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

E M Ocio

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

M-Á Montalbán

7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

L Corchete

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

M-J Terol

12

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

M-A Echeveste

13

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

R De Paz

14

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

F De Arriba

15

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

L Palomera

16

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

J de la Rubia

17

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

J Díaz-Mediavilla

18

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

M Granell

19

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

A Gorosquieta

20

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

A Alegre

21

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

J-J Lahuerta

23

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

J Bladé

24

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

J F San Miguel

25

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group

26

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

publication date

7 June 2013

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

27

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

2056-2061

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

https://scigraph.springernature.com/pub.10.1038/leu.2013.166

0 references

Can multiple myeloma become a curable disease?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

How I treat multiple myeloma in younger patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Have drug combinations supplanted stem cell transplantation in myeloma?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Lenalidomide in myeloma--a high-maintenance friend.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

The role of complete response in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

The genetic architecture of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Molecular pathogenesis of multiple myeloma and its premalignant precursor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Exome sequencing in tracking clonal evolution in multiple myeloma following therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Clonal competition with alternating dominance in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Will the real myeloma please stand up?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Diagnosis of smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

21 January 2018

Consolidation therapy in myeloma: a consolidated approach?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

7 January 2021

based on heuristic

inferred from DOI database lookup

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.166

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2013.166

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/23743858

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46440869&oldid=2111772759"